July 11, 2024

The Global Metabolism Drugs Market Growth Is Projected To Driven By Increased Obesity Rates

Metabolism drugs are designed to aid weight loss and includes both prescription and over-the-counter drugs such as appetite suppressants, fat blockers, and carb blockers. These drugs work by either increasing feelings of fullness to reduce appetite, blocking the absorption of fat, or decreasing the digestion and absorption of carbohydrates. The growing prevalence of obesity globally has led to a rise in demand for weight loss products. According to WHO, over 650 million adults are obese worldwide. The high obesity rates in countries such as the U.S and China have made these important markets for metabolism drugs.

The global Metabolism Drugs Market is estimated to be valued at Us$ 9410.88 Mn in 2024 and is expected to exhibit a CAGR Of 2.3% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the metabolism drugs market is the rising demand for herbal supplements and nutritional therapies as an alternative to prescription drugs. Many consumers are preferring natural products over pharmaceuticals due to potential side effects of the latter. Also, nutrition-based therapies allow for lifestyle changes which provide long-term results. Manufacturers are therefore focusing on developing herbal formulations and plant-based supplements for weight management. Furthermore, the market has witnessed a surge in new product launches catering to niche consumer segments such as vegan metabolism drugs and drugs aimed at PCOS (Polycystic Ovary Syndrome) patients. Customized and targeted weight loss solutions based on individual metabolic rates and genetics is another upcoming trend in this industry.

Porter’s Analysis

Threat of new entrants: The threat is moderate due to high capital required for R&D and regulatory barriers. However, large pool of startups is entering the market.

Bargaining power of buyers: Buyers have moderate to high bargaining power due to availability of substitutes and potential of generic drugs.

Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to presence of number of suppliers and intangible nature of innovation.

Threat of new substitutes: Threat is high from new mechanisms of action and alternative therapies like microbiome therapeutics and gene therapies.
Competitive rivalry: The rivalry is high due to presence of major players, regulatory approvals, and high R&D investments required.

Key Takeaways

The Global Metabolism Drugs Market Size is expected to witness high growth driven by increasing prevalence of metabolic disorders, rising awareness, and growing geriatric population globally. The global Metabolism Drugs Market is estimated to be valued at US$ 9410.88 Mn in 2024 and is expected to exhibit a CAGR of 2.3% over the forecast period 2024 to 2031.

Regional analysis –

 

North America dominated the market and is expected to maintain its dominance during the forecast period owing to high awareness, growing obese population, and presence of major players in the region. Asia Pacific is expected to witness fastest growth over the forecast period driven by large patient population, rising healthcare expenditure, and growing middle class in the region.

Key players operating in the Metabolism Drugs Market are 3M, Ajinomoto Co., Eli Lilly and Company, Evonik Industries AG, Merck KGaA, Novartis AG, Takeda Pharmaceutical Company Limited, etc. Developments in drug formulations, increasing R&D spending, and partnerships are some of the key strategies adopted by major players to gain competitive advantage in the market.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it